Loading patent…
AssigneeThe Runatek Corporation
InventorMatthew Lucci
Estimating the term…
This disclosure relates to a method for determining the presence of acetaminophen in a human patient through the use of continuous glucose monitors, such as continuous analyte sensors. One of the sensors is subject to the distortion caused by acetaminophen interference with the sensor's oxidation reaction, and one of the sensors is not impacted by such distortion, allowing for a measurement of the difference between the glucose measurements of these two sensors. This disclosure also relates to a method for determining the concentration of medications co-administered or combined with acetaminophen in a human patient through similar means.
A method of determining the plasma concentration of acetaminophen by measuring the effect of the acetaminophen's distortion of blood glucose readings through continuous analyte sensors, comprising (a) an accurate, non-distorted reading of the plasma glucose concentration, and (b) a continuous glucose monitor (CGM) with a consistent and observable distortion due to acetaminophen interference, and (c) a computer algorithm that utilizes the values and difference in values measured from (a) and (b) as inputs to determine the concentration of acetaminophen present in the patient's blood plasma.
A method for determining the blood plasma concentration of acetaminophen in a patent's system, comprising (a) a CGM with a consistent and observable distortion due to acetaminophen interference, and (b) a separate CGM with a consistent and observable distortion due to acetaminophen interference that produces plasma glucose readings that are consistently and observably different from those produced by (a), and (c) a computer algorithm that utilizes the values and difference in values measured from (a) and (b) as inputs to determine the concentration of acetaminophen present in the patient's blood plasma.
Dependencies are inferred from the claim text.